Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1954 1
1958 1
1959 1
1960 2
1962 1
1963 1
1964 2
1965 1
1966 3
1967 3
1969 6
1970 2
1971 6
1972 2
1973 2
1974 3
1975 4
1976 1
1977 4
1978 5
1979 6
1980 5
1981 6
1982 6
1983 14
1984 8
1985 10
1986 19
1987 14
1988 8
1989 17
1990 17
1991 19
1992 6
1993 14
1994 39
1995 30
1996 12
1997 11
1998 14
1999 23
2000 19
2001 21
2002 19
2003 22
2004 18
2005 14
2006 24
2007 11
2008 20
2009 38
2010 28
2011 30
2012 39
2013 45
2014 36
2015 44
2016 56
2017 67
2018 56
2019 63
2020 106
2021 97
2022 87
2023 81
2024 64
2025 66

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,401 results

Results by year

Filters applied: . Clear all
Page 1
MEN1 mutations mediate clinical resistance to menin inhibition.
Perner F, Stein EM, Wenge DV, Singh S, Kim J, Apazidis A, Rahnamoun H, Anand D, Marinaccio C, Hatton C, Wen Y, Stone RM, Schaller D, Mowla S, Xiao W, Gamlen HA, Stonestrom AJ, Persaud S, Ener E, Cutler JA, Doench JG, McGeehan GM, Volkamer A, Chodera JD, Nowak RP, Fischer ES, Levine RL, Armstrong SA, Cai SF. Perner F, et al. Among authors: nowak rp. Nature. 2023 Mar;615(7954):913-919. doi: 10.1038/s41586-023-05755-9. Epub 2023 Mar 15. Nature. 2023. PMID: 36922589 Free PMC article. Clinical Trial.
Targeted protein degradation: from mechanisms to clinic.
Tsai JM, Nowak RP, Ebert BL, Fischer ES. Tsai JM, et al. Among authors: nowak rp. Nat Rev Mol Cell Biol. 2024 Sep;25(9):740-757. doi: 10.1038/s41580-024-00729-9. Epub 2024 Apr 29. Nat Rev Mol Cell Biol. 2024. PMID: 38684868 Review.
Biological Activity of Berberine-A Summary Update.
Och A, Podgórski R, Nowak R. Och A, et al. Among authors: nowak r. Toxins (Basel). 2020 Nov 12;12(11):713. doi: 10.3390/toxins12110713. Toxins (Basel). 2020. PMID: 33198257 Free PMC article. Review.
A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
Nowak RJ, Benatar M, Ciafaloni E, Howard JF Jr, Leite MI, Utsugisawa K, Vissing J, Rojavin M, Li Q, Tang F, Wu Y, Rampal N, Cheng S; MINT Investigators. Nowak RJ, et al. N Engl J Med. 2025 Jun 19;392(23):2309-2320. doi: 10.1056/NEJMoa2501561. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202593 Clinical Trial.
B cells in the pathophysiology of myasthenia gravis.
Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O'Connor KC. Yi JS, et al. Among authors: nowak rj. Muscle Nerve. 2018 Feb;57(2):172-184. doi: 10.1002/mus.25973. Epub 2017 Sep 30. Muscle Nerve. 2018. PMID: 28940642 Free PMC article. Review.
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
Antozzi C, Vu T, Ramchandren S, Nowak RJ, Farmakidis C, Bril V, De Bleecker J, Yang H, Minks E, Park JS, Grudniak M, Smilowski M, Sevilla T, Hoffmann S, Sivakumar K, Suzuki Y, Youssef E, Sanga P, Karcher K, Zhu Y, Sheehan JJ, Sun H; Vivacity-MG3 Study Group. Antozzi C, et al. Among authors: nowak rj. Lancet Neurol. 2025 Feb;24(2):105-116. doi: 10.1016/S1474-4422(24)00498-8. Lancet Neurol. 2025. PMID: 39862879 Clinical Trial.
Small-molecule-induced polymerization triggers degradation of BCL6.
Słabicki M, Yoon H, Koeppel J, Nitsch L, Roy Burman SS, Di Genua C, Donovan KA, Sperling AS, Hunkeler M, Tsai JM, Sharma R, Guirguis A, Zou C, Chudasama P, Gasser JA, Miller PG, Scholl C, Fröhling S, Nowak RP, Fischer ES, Ebert BL. Słabicki M, et al. Among authors: nowak rp. Nature. 2020 Dec;588(7836):164-168. doi: 10.1038/s41586-020-2925-1. Epub 2020 Nov 18. Nature. 2020. PMID: 33208943 Free PMC article.
Plasticity in binding confers selectivity in ligand-induced protein degradation.
Nowak RP, DeAngelo SL, Buckley D, He Z, Donovan KA, An J, Safaee N, Jedrychowski MP, Ponthier CM, Ishoey M, Zhang T, Mancias JD, Gray NS, Bradner JE, Fischer ES. Nowak RP, et al. Nat Chem Biol. 2018 Jul;14(7):706-714. doi: 10.1038/s41589-018-0055-y. Epub 2018 Jun 11. Nat Chem Biol. 2018. PMID: 29892083 Free PMC article.
Structural basis of regulated m7G tRNA modification by METTL1-WDR4.
Li J, Wang L, Hahn Q, Nowak RP, Viennet T, Orellana EA, Roy Burman SS, Yue H, Hunkeler M, Fontana P, Wu H, Arthanari H, Fischer ES, Gregory RI. Li J, et al. Among authors: nowak rp. Nature. 2023 Jan;613(7943):391-397. doi: 10.1038/s41586-022-05566-4. Epub 2023 Jan 4. Nature. 2023. PMID: 36599985 Free PMC article.
Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
Bourgeois W, Cutler JA, Aubrey BJ, Wenge DV, Perner F, Martucci C, Henrich JA, Klega K, Nowak RP, Donovan KA, Boileau M, Wen Y, Hatton C, Apazidis AA, Olsen SN, Kirmani N, Pikman Y, Pollard JA, Perry JA, Sperling AS, Ebert BL, McGeehan GM, Crompton BD, Fischer ES, Armstrong SA. Bourgeois W, et al. Among authors: nowak rp. Blood. 2024 Apr 11;143(15):1513-1527. doi: 10.1182/blood.2023021105. Blood. 2024. PMID: 38096371 Free PMC article.
1,401 results